A carregar...
Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment
Approximately 15% of patients with coronavirus disease 2019 (COVID-19) experience severe disease, and 5% progress to critical stage that can result in rapid death. No vaccines or antiviral treatments have yet proven effective against COVID-19. Patients with severe COVID-19 experience elevated plasma...
Na minha lista:
| Publicado no: | Clin Immunol |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
The Authors. Published by Elsevier Inc.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7308779/ https://ncbi.nlm.nih.gov/pubmed/32585295 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clim.2020.108517 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|